Lite Strategy (LITS) Net Income (2010 - 2026)
Lite Strategy (LITS) posted quarterly Net Income of -$22.4 million for Q1 2026, down 617.76% year-over-year from $4.3 million in Q1 2025, and up 26.96% quarter-over-quarter from -$30.7 million in Q4 2025.
Lite Strategy (LITS) Net Income (2010 - 2026) Analysis & Trends
Lite Strategy's Net Income history runs 17 years deep, the most recent figure standing at -$22.4 million for Q1 2026.
- In Q1 2026, Net Income fell 617.76% year-over-year to -$22.4 million; the TTM figure through Mar 2026 stood at -$133.1 million (down 193.99% YoY), while the FY2025 annual figure was -$90.1 million, down 2242.36% from the prior year.
- Net Income for Q1 2026 stood at -$22.4 million, up from -$30.7 million in the prior quarter.
- The five-year high for Net Income was $53.0 million in Q3 2023, with the low at -$76.4 million in Q2 2025.
- The 5-year median for Net Income is -$11.6 million (2023), against an average of -$15.2 million.
- The sharpest annual moves came in 2023 and 2025: Net Income soared 247.88% in 2023, then slumped 760.94% in 2025.
- Lite Strategy's Net Income stood at $5.6 million in 2022, then sank by 306.78% to -$11.6 million in 2023, then soared by 69.42% to -$3.6 million in 2024, then plunged by 760.94% to -$30.7 million in 2025, then grew by 26.96% to -$22.4 million in 2026.
- Business Quant data shows LITS's Net Income at -$22.4 million in Q1 2026, -$30.7 million in Q4 2025, and -$3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | -21.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.39 Mn |
| Dec 31, 2025 | -30.66 Mn |
| Sep 30, 2025 | -3.64 Mn |
| Jun 30, 2025 | -76.39 Mn |
| Mar 31, 2025 | -3.12 Mn |
| Dec 31, 2024 | -3.56 Mn |
| Sep 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -30.23 Mn |
| Mar 31, 2024 | -9.71 Mn |
| Dec 31, 2023 | -11.64 Mn |
| Sep 30, 2023 | 52.96 Mn |
| Jun 30, 2023 | -10.58 Mn |
| Mar 31, 2023 | -32.38 Mn |
| Dec 31, 2022 | 5.63 Mn |
| Sep 30, 2022 | -35.82 Mn |
| Jun 30, 2022 | -16.37 Mn |
| Mar 31, 2022 | -21.88 Mn |
| Dec 31, 2021 | -21.05 Mn |
| Sep 30, 2021 | -24.23 Mn |
| Jun 30, 2021 | -69.17 Mn |